Li-Xia Yang

Li-Xia Yang


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2016 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
JYJinshan Ye
Jinshan Ye
RGRuiwei Guo
Ruiwei Guo
YSYankun Shi
Yankun Shi
FQFeng Qi
Feng Qi
CGChuanming Guo
Chuanming Guo
LYLi-Xia Yang
Li-Xia Yang
Inflammation response plays a critical role in all phases of atherosclerosis (AS). Increased evidence has demonstrated that miR-155 mediates inflammatory mediators in macrophages to promote plaque formation and rupture. However, the precise mechanism of miR-155 remains unclear in AS. Here, we also found that miR-155 and PDCD4 were elevated in the aortic tissue of atherosclerotic mice and ox-LDL treated RAW264.7 cells. Further studies showed that miR-155 not only directly inhibited SOCS1 expression, but also increased the expression of p-STAT and PDCD4, as well as the production of proinflammation mediators IL-6 and TNF-α. Downregulation of miR-155 and PDCD4 and upregulation of SOCS1 obviously decreased the IL-6 and TNF-αexpression. In addition, inhibition of miR-155 levels in atherosclerotic mice could notably reduce the IL-6 and TNF-αlevel in plasma and aortic tissue, accompanied with increased p-STAT3 and PDCD4 and decreased SOCS1. Thus, miR-155 might mediate the inflammation in AS via the SOCS1-STAT3-PDCD4 axis. These results provide a rationale for intervention of intracellular miR-155 as possible antiatherosclerotic targets.

3 September 2019 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
JYJinshan Ye
Jinshan Ye
YWYaxi Wu
Yaxi Wu
RGRuiwei Guo
Ruiwei Guo
WZWenjun Zeng
Wenjun Zeng
YDYanan Duan
Yanan Duan
LYLi-Xia Yang
Li-Xia Yang
Atherosclerosis (AS) is a chronic inflammatory disease, and macrophages play a key role in all phases of AS. Recent studies have shown that miR-221 is a biomarker for AS and stroke; however, the role and mechanism of miR-221 in AS are unclear. Herein, we found that miR-221 and NCoR levels were decreased in ox-LDL-treated THP-1-derived macrophages. In contrast, DNMT3b, IL-6, and TNF-αexpression levels were increased under these conditions. Upregulation of miR-221 or NCoR could partially inhibit ox-LDL-induced IL-6 and TNF-αexpression. Further studies showed that DNMT3b was a target of miR-221. DNMT3b inhibition also suppressed IL-6 and TNF-αexpression and increased NCoR expression in the presence of ox-LDL. Moreover, DNMT3b was involved in ox-LDL-induced DNA methylation in the promoter region of NCoR. These findings suggest that miR-221 suppresses ox-LDL-induced inflammatory responses via suppressing DNMT3b-mediated DNA methylation in the promoter region of NCoR. These results provide a rationale for using intracellular miR-211 as a possible antiatherosclerotic target.

7 June 2018 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
YWYaxi Wu
Yaxi Wu
JYJinshan Ye
Jinshan Ye
RGRuiwei Guo
Ruiwei Guo
XLXing Liang
Xing Liang
LYLi-Xia Yang
Li-Xia Yang
Toll/IL-1R-domain-containing adaptor-inducing IFN-β (TRIF) is an important adaptor for TLR3- and TLR4-mediated inflammatory signaling pathways. Recent studies have shown that TRIF plays a key role in vessel inflammation and atherosclerosis; however, the precise mechanisms are unclear. We investigated the mechanisms of the TRIF-regulated inflammatory response in RAW264.7 macrophages under oxidized low-density lipoprotein (ox-LDL) stimulation. Our data show that ox-LDL induces TRIF, miR-155, and BIC expression, activates the ERK1/2 and SOCS1-STAT3-NF-κB signaling pathways, and elevates the levels of IL-6 and TNF-α in RAW264.7 cells. Knockdown of TRIF using TRIF siRNA suppressed BIC, miR-155, IL-6, and TNF-α expression and inhibited the ERK1/2 and SOCS1-STAT3-NF-κB signaling pathways. Inhibition of ERK1/2 signaling also suppressed BIC and miR-155 expression. These findings suggest that TRIF plays an important role in regulating the ox-LDL-induced macrophage inflammatory response and that TRIF modulates the expression of BIC/miR-155 and the downstream SOCS1-STAT3-NF-κB signaling pathway via ERK1/2. Therefore, TRIF might be a novel therapeutic target for atherosclerosis.

6 January 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YCYu Chen
Yu Chen
XZXin Zhang
Xin Zhang
QYQing Ye
Qing Ye
NCNing Cao
Ning Cao
SLShao-Ying Li
Shao-Ying Li
LYLi-Xia Yang
Li-Xia Yang
High altitude exposure increases the risk of myocardial ischemia (MI) and subsequent cardiovascular death. Machine learning techniques have been used to develop cardiovascular disease prediction models, but no reports exist for high altitude induced myocardial ischemia. Our objective was to establish a machine learning-based MI prediction model and identify key risk factors. Using a prospective cohort study, a predictive model was developed and validated for high-altitude MI. We consolidated the health examination and self-reported electronic questionnaire data (collected between January and June 2022 in 920th Joint Logistic Support Force Hospital of china) of soldiers undergoing high-altitude training, along with the health examination and second self-reported electronic questionnaire data (collected between December 2022 and January 2023) subsequent to their completion on the plateau, into a unified dataset. Participants were subsequently allocated to either the training or test dataset in a 3:1 ratio using random assignment. A predictive model based on clinical features, physical examination, and laboratory results was designed using the training dataset, and the model's performance was evaluated using the area under the receiver operating characteristic curve score (AUC) in the test dataset. Using the training dataset (n = 2141), we developed a myocardial ischemia prediction model with high accuracy (AUC = 0.86) when validated on the test dataset (n = 714). The model was based on five laboratory results: Eosinophils percentage (Eos.Per), Globulin (G), Ca, Glucose (GLU), and Aspartate aminotransferase (AST). Our concise and accurate high-altitude myocardial ischemia incidence prediction model, based on five laboratory results, may be used to identify risks in advance and help individuals and groups prepare before entering high-altitude areas. Further external validation, including female and different age groups, is necessary.

1 January 2018 in International Heart Journal
Verified
Journal Article
Closed access
PDF file
CYChen Yu
Chen Yu
LYLi-Xia Yang
Li-Xia Yang
GRGuo Ruiwei
Guo Ruiwei
SYShi Yankun
Shi Yankun
YJYe Jinshan
Ye Jinshan
To investigate whether focal adhesion kinase (FAK) can participate in the secretion of matrix metalloproteinase 9 (MMP9) after CD147 stimulation in THP-1 induced macrophages; thus, to explore the potential treatment perspectives for acute coronary syndrome (ACS). Phorbol-12-myristate-13-acetate (PMA) was used to induce THP-1 cells to differentiate into macrophages. To confirm the peak mRNA and protein expression of FAK and MMP9 after the stimulation of CD147, the macrophages were divided into 5 groups (0, 3, 6, 9, and 12 hours), with 0 hours group as control group. To investigate the role of FAK in the secretion of MMP9, with stimulation of CD147 for 9 hours, FAK inhibitor 14 was used to inhibit FAK Y397 phosphorylation. The mRNA and protein expressions were quantified by qRT-PCR and western blotting, respectively. (1) Relative mRNA expression of FAK and MMP9 were both significantly up-regulated (all P < 0.05) after stimulation of CD147, FAK peaked at 9 hours (3.908 ± 0.106 versus 1, P < 0.05), whereas MMP9 peaked at 6 hours (2.522 ± 0.062 versus 1, P < 0.05). (2) Relative protein expression of FAK, pFAK, and MMP9 were all significantly increased after CD147 stimulation (all P < 0.05), FAK (1.930 ± 0.024 versus 1, P < 0.05) and pFAK (1.737 ± 0.021 versus 1, P < 0.05) peaked at 9 hours, whereas MMP9 peaked at 6 hours (1.527 ± 0.033 versus 1, P < 0.05). (3) CD147 up-regulates FAK, pFAK, and MMP9 mRNA and protein expressions in a dose-dependent manner. (4) FAK inhibitor 14 significantly reduced the relative protein expression level of pFAK (0.077 ± 0.012 versus 1, P < 0.05) and MMP9 (0.133 ± 0.012) at 9 hours after CD147 stimulation. The results demonstrated that FAK Y397 phosphorylation was involved in the secretion of MMP9 after CD147 stimulation in macrophages and may play a role in the regulation of ACS.

5 July 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
XWXiaoming Wang
Xiaoming Wang
CCChangzheng Chen
Changzheng Chen
ZYZhihua Yang
Zhihua Yang
YCYu Chen
Yu Chen
JFJun Fan
Jun Fan
LYLi-Xia Yang
Li-Xia Yang
This study comprehensively examines the global burden of atrial fibrillation and atrial flutter (AF/AFL) attributable to high alcohol use from 1990 to 2021, analyzing temporal trends, regional disparities, and sociodemographic determinants using data from the Global Burden of Disease Study 2021 (GBD 2021). We extracted GBD 2021 estimates on deaths, disability-adjusted life years (DALYs), and age-standardized rates (ASRs) for AF/AFL due to high alcohol use across 204 countries. Joinpoint analysis and age-period-cohort (APC) modeling were employed to assess temporal trends and disentangle age, period, and cohort effects. In 2021, AF/AFL attributable to high alcohol use contributed to 11,908 deaths (95% UI: 8,860, 14,981) and 362,698 DALYs (95% UI: 263,321, 465,594) globally, marking increases of 176.4% and 132.9%, respectively, since 1990. While age-standardized death rates (ASDR) remained stable (0.2 per 100,000), males bore 2.3-fold higher mortality and 3.7-fold greater DALYs than females. Western Europe had the highest burden (4,589 deaths; 109,934 DALYs), while Oceania reported the lowest (2 deaths; 68 DALYs). High Socio-Demographic Index (SDI) regions exhibited the largest absolute burden, yet low-middle SDI regions experienced the steepest ASDR growth (estimated annual percentage change (EAPC) of ASDR is 2.01%). APC models revealed diverging sex-specific trends: male mortality marginally increased (net drift = 0.091%/year) versus significant female declines (–0.925%/year). The mortality rates are notably elevated in the age groups of 30–39 and those over 75 years, with the highest peak observed in individuals aged 95 and above. AF/AFL attributable to high alcohol use remains a critical public health challenge, disproportionately affecting males, high-SDI regions, and aging populations. Targeted interventions addressing alcohol consumption patterns, gender-specific risk mitigation, and healthcare disparities are urgently needed to reduce the growing burden, particularly in regions with accelerating trends.